Accessing BPC-157 in Canada Canadian researchers and individuals interested in BPC-157 navigate a regulatory landscape that differs from both complete prohibition and full pharmaceutical approval
according to the National Academies of Sciences, Engineering, and Medicine, absorption is approximately 50% at 1 mcg but falls to roughly 1.3% at 1,000 mcg
According to NICE Clinical Knowledge Summaries and the British National Formulary (BNF), the recommended treatment regimens are: For patients without neurological involvement : Initial treatment: hydroxocobalamin 1 mg intramuscularly three times a week for 2 weeks Maintenance: hydroxocobalamin 1 mg intramuscularly every 3 months for life For patients with neurological involvement : Initial treatment: hydroxocobalamin 1 mg intramuscularly on alternate days until no further improvement Maintenance: hydroxocobalamin 1 mg intramuscularly every 2 months for life If neurological symptoms are present, treatment should be started urgently to prevent irreversible damage
Patients interested in this approach can review our NAD+ treatment program in Doral, FL for a full overview of how we structure the protocol
Higher exposure and a smaller fat reserve suggest greater side-effect and lean-mass risk, but no long-term trial has measured the outcome
skin feels softer Oily/Acne-Prone: calmer skin with slight smoothing of surface texture Normal/Combination: subtle glow and balanced texture Weeks 34: Cellular Turnover All skin types: increased cellular turnover, leading to firmer texture Dry/Sensitive: stronger skin barrier, improved moisture retention, gentle plumping Oily/Acne-Prone: faster healing of minor breakouts, smoother appearance Normal/Combination: noticeable elasticity and recovery from minor stressors Weeks 68+: Structural Improvements All skin types: firmer, more resilient skin
